NCT02234960View on ClinicalTrials.gov

Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA)

CompletedOBSERVATIONAL

Enrollment

102

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Tocilizumab

Tocilizumab will be given according to summary of product characteristics as per clinical practice.

Trial Locations (15)

85-168

Bydgoszcz

85-681

Bydgoszcz

41-902

Bytom

63-100

Gmina Śrem

30-119

Krakow

Unknown

Krakow

20-954

Lublin

10-045

Olsztyn

61-285

Poznan

98-200

Sieradz

81-759

Sopot

27-200

Starachowice

34-200

Sucha Beskidzka

43-450

Ustroń

50-981

Wroclaw

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT02234960 - Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA) | Biotech Hunter | Biotech Hunter